<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1305257384
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1987
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DIPROFOS INJ. 2ML
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BETAMETHASONE DIPROPIONATE,BETAMETHASONE SODIUM PHOSPHATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5,2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        25.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Organon Heist bv" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Organon Heist bv
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Organon Belgium
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        D07AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Diprofos &nbsp;belongs to a group of medicines called &quot;corticosteroids&quot;. These medicines help relieve parts of the body affected by inflammation. They work by reducing swelling, redness, itching and allergic reactions. They are used to treat a number of problems.</p><p>&nbsp;</p><p>Diprofos &nbsp;is used in inflammatory conditions requiring systemic corticosteroid treatment, in particular:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arthritis, bursitis, sciatica, lumbago or other disorders of bone or deep tissue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic conditions such as asthma, hay fever, bronchitis, allergies to medicine, bites or insect bites</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin conditions such as inflammation, itching, hives, hair loss, psoriasis, scarring or cystic acne</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other conditions diagnosed by your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to the active substances or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to other corticosteroids.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a fungal infection - please tell your doctor before using Diprofos . Your doctor may want to treat the infection before you use Diprofos .</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before using Diprofos . Tell your doctor before using this medicine:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are diabetic</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have thyroid problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have epilepsy or seizures</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have eye problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a viral or bacterial infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have stomach or intestinal problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have high blood pressure or heart problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have muscle weakness or loss of calcium</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of psychiatric illness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you need to be vaccinated.</p><p>&nbsp;</p><p>Contact your doctor if you experience blurred vision or other visual disturbances.</p><p>&nbsp;</p><p>Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use.</p><p>&nbsp;</p><p>Children and adolescents</p><p>As corticosteroids can disturb the growth of infants and children, it is important for your doctor to monitor their growth and development carefully in case of prolonged treatment.</p><p>&nbsp;</p><p>Other medicines and Diprofos</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, please tell your doctor or pharmacist if you are taking any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-epileptic medicines,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hormonal medicines,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for the heart or blood problems, such as diuretics.</p><p>&nbsp;</p><p>This is because it may be necessary to change the dose of certain medicines while you are using Diprofos .</p><p>&nbsp;</p><p>Please also tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-inflammatory medicines.</p><p>&nbsp;</p><p>Because it is possible that your stomach or intestine will not function properly if you take these medicines while using Diprofos .</p><p>&nbsp;</p><p>Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>Some medicines may increase the effects of Diprofos and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat).</p><p>&nbsp;</p><p>Remember to tell your doctor that you are using Diprofos if he/she plans to have you undergo certain laboratory tests.</p><p>&nbsp;</p><p>Diprofos with food, drink and alcohol</p><p>Do not drink alcohol while using Diprofos , as this could cause problems with your stomach or intestine.</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Indeed it is not known if Diprofos can be used safely during pregnancy and lactation.</p><p>In case of treatment with corticosteroids during pregnancy, both the mother and the child should be carefully monitored during labor and after birth.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist before taking any medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>In general, Diprofos does not affect coordination or the ability to react. However, in cases of high dosage or prolonged treatment, some patients may experience an exaggerated sense of well-being (euphoria), or drowsiness or vision problems, which may affect their ability to drive a vehicle.</p><p>&nbsp;</p><p><strong>Diprofos contains 9&nbsp;mg benzyl alcohol in each ml. </strong></p><p>Benzyl alcohol may cause allergic reactions. Benzyl alcohol has been linked with the risk of severe side effects including breathing problems (called &ldquo;gasping syndrome&rdquo;) in young children. Do not give to your newborn baby (up to 4 weeks old), unless recommended by your doctor. Do not use for more than a week in young children (less than 3 years old), unless advised by your doctor or pharmacist.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice if you are pregnant or breast feeding, or if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called &ldquo;metabolic acidosis&rdquo;).</p><p>&nbsp;</p><p><strong>Diprophos contains sodium </strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p><strong>Diprofos </strong><strong>&nbsp;</strong><strong>contains</strong><strong> </strong><strong>methyl</strong><strong> </strong><strong>parahydroxybenzoate</strong><strong> </strong><strong>(E218)</strong><strong> </strong><strong>and propyl</strong><strong> </strong><strong>parahydroxybenzoate</strong><strong> </strong><strong>(E216</strong>) &ndash; which may cause allergic reactions (possibly delayed) and exceptionally, difficulty breathing.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Diprofos &nbsp;is a suspension for injection. It must be shaken before use. The injection is usually done by your doctor or a health professional. Your doctor will determine the dose depending on your needs.</p><p>&nbsp;</p><p>The injection can be intramuscular, intra-articular, periarticular, intralesional, intradermal or administered in the synovial bursa. It can also be injected into soft tissues.</p><p>&nbsp;</p><p>Diprofos &nbsp;cannot be used for intravenous or subcutaneous administration.</p><p>&nbsp;</p><p>If you use more Diprofos &nbsp;than you should</p><p>Your doctor will regularly check that you are receiving the correct dose.</p><p>&nbsp;</p><p>If you have received too much Diprofos , immediately contact your doctor, pharmacist or the Poison Control Center (070/245.245).</p><p>&nbsp;</p><p>If you forget to use Diprofos</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you stop using Diprofos</p><p>Do not abruptly stop using Diprofos . The dose should be reduced slowly by your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The side effects associated with corticosteroids, including Diprofos , depend on the dose and duration of treatment.</p><p>&nbsp;</p><p>You can develop the following side effects during treatment with Diprofos :</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in your heart rate, increase in blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness, muscle pain, loss of calcium</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; water retention</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thinning of the skin, ecchymoses (bruising), facial flushing, slow wound healing, hypersensitivity reactions, increased sweating, hives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain disorders of the stomach or intestine such as ulcers, hiccups</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures, exaggerated feeling of well-being (euphoria), difficulty sleeping (insomnia), dizziness, headache, mood fluctuation, severe depression, excessive irritability, psychotic reactions, particularly in patients with a history of psychiatric disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye disorders, e.g., cataract, glaucoma or protrusion of the eyeball from its usual place</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moon face (facial swelling), acne, menstrual and libido disorders, increased requirements for insulin or oral antidiabetic medicines in patients with diabetes, symptoms of latent diabetes mellitus</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slower growth of the fetus or child</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inhibition of skin tests</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; masking of the symptoms of infection, activation of a latent infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased resistance to infection, especially when caused by mycobacteria, tuberculosis,</p><p><em>Candida albicans </em>or viruses.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, tell your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system: The National Pharmacovigilance and Drug Safety Centre (NPC), (SFDA).</p><p>&nbsp;</p><p>By reporting side effects, you are helping to provide more information on the safety of the medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p><u>Diprofos &nbsp;Ampoule:</u></p><p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton after EXP. is written in both inner label &amp; outer pack</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Diprofos &nbsp;contains</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are 6,43 mg/ml betamethasone dipropionate (equivalent to 5 mg of betamethasone) and 2,63 mg/ml betamethasone disodium phosphate (equivalent to 2 mg of betamethasone).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: disodium phosphate dihydrate*, sodium chloride, disodium edetate, polysorbate 80, benzyl alcohol (E1519), methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium carboxymethylcellulose, macrogols, hydrochloric acid, water for injections, nitrogen.</p><p>*Anhydrous form for <u>Diprofos &nbsp;Disposable Syringe.</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Diprofos  Ampoule:
 Boxes containing 1 ampoule of 1 ml Boxes containing 3 ampoules of 1 ml Boxes containing 1 ampoule of 2 ml Boxes containing 3 ampoules of 2 ml

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><u>Marketing Authorization Holder</u><u>:</u><u> </u></p><p>MSD Belgium BVBA/SPRL, Close du Lynx,5, 1200 Brussels, Belgium</p><p>&nbsp;</p><p><u>Manufacturer: </u></p><p>Schering-Plough Labo N.V, Industriepark 30, B-22220 Heist-op-den-Belgium</p><p>&nbsp;</p><p>Medicinal product subject to medical prescription.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in April 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي ديبروفوس إلى أسرة الأدوية المعروفة بالكورتيكوستيوريد التي تُساعد على تخفيف وطأة الإلتهاب على بعض أجزاء الجسم، وذلك من خلال الحدّ من التورم، والاحمرار، والحكة، وردود فعل الحساسيّة. ويُستخدَم لمعالجة عدد من الأعراض.</p><p dir="RTL">يُستخدَم ديبروفوس في الحالات الالتهابيّة التالية التي تحتاج إلى علاج جهازي بالكورتيكوسيترويد، لا سيما:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل، أو التهاب حويصلة الورك، أو الألم في العصب الوركي، أو الألم القطني، أو أي حالات أخرى في العظام أو في الأنسجة العميقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات الحساسيّة، مثل داء الربو، أو حمى القشّ، أو التهاب الشُعب الهوائيّة، أو الحساسيّة من الأدوية، أو لدغات أو لسعات الحشرات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات البشرة، مثل الالتهاب، أو الحكة، أو الشرى، أو فقدان الشعر، أو داء الصدفيّة، أو الندبات، أو حب الشباب الكيسي؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مشاكل أخرى شخّصها طببيك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع إستعمال ديبروفوس:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حساسيّة من المادة الفعّالة أو أحد مكونات الدواء الأخرى المدرجة في البند 6.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حساسيّة من أي كورتيكوستيرويدات أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال الاصابة بالفطريّات &ndash; اخبر الطبيب قبل استخدام ديبروفوس. قد يريد الطبيب معالجة الالتهاب قبل تناولك ديبروفوس.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات والوقاية</strong></p><p dir="RTL">اخبر الطبيب أو الصيدلي قبل تناول ديبروفوس</p><p dir="RTL">&nbsp;</p><p dir="RTL">اخبر الطبيب قبل البدء باستخدام هذا الدواء في الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بداء السكري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمشاكل في الغدة الدرقيّة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بداء الصرع أو تتعرّض لتشنّجات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في العينَيْن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالتهاب فيروسي أو بكتيري</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في المعدة أو الأمعاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان ضغط دمك مرتفعًا أو إذا كان لديك مشاكل في القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بوهن في العضلات أو بنقص في الكالسيوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أمراض نفسيّة سابقه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت بحاجة إلى تطعيم</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك إذا عانيت من عدم وضوح الرؤية أو الاضطرابات البصرية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض عصبية خطيرة، وبعضها أدى إلى الوفاة، ذكرت في حالات حقن الكورتيزون فوق الجافية. وتشمل أعراض محددة منها، من بين أمور أخرى، احتشاء الحبل الشوكي، الشلل النصفي والرباعي، والعمى القشري، والسكتة الدماغية. وقد تم الإبلاغ عن هذه الأعراض العصبية الخطيرة مع وبدون استخدام التنظير. لم تُنشر سلامة وفعالية حقن كورتيكوستيرويد فوق الجافية، ولم يتم الموافقة عليها لهذا النوع من الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">بما أن الكورتيوستيرويد قد يؤثّر على نموّ الأطفال والرضع، من المهمّ أن يُراقب الطبيب نموّهم وتطوّرهم عن كثب في حال متابعة العلاج لمدّة طويلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وديبروفوس</strong></p><p dir="RTL">يُرجى إخبار الطبيب أو الصيدلي في حال كنت تتناول أو تناولت مؤخّرًا أو تنوي تناول أية أدوية أخرى.</p><p dir="RTL">وبشكل خاص، أخبر الطبيب او الصيدلي إذا كنت تتناول أيًّا من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مضادة لداء الصرع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيويّة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الهرمونيّة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية لمشاكل الدم والقلب، مثل الأدويّة المدرّة للبول.</p><p dir="RTL">وذلك نظرًا إلى أنّه قد يكون من الضروري تعديل جرعة بعض الأدوية عند تناول ديبروفوس.</p><p dir="RTL">أخبر الطبيب أو الصيدلي في حال كنت تتناول أيًا من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للالتهابات</p><p dir="RTL">وذلك لأنّ معدتك أو أمعاؤك قد لا تعمل بالكفاءة المعتاده إذا تناولت هذه الأدوية في الوقت نفسه مع ديبروفوس.</p><p dir="RTL">یرجی إخبار طبیبك إذا کنت تتناول أو تناولت مؤخرا أدویة أخرى، بما في ذلك الأدویة التي تم الحصول عليها بدون وصفة طبیة.<br />قد تؤدي بعض الأدویة إلى زيادة تأثير (إسم المستحضر) وقد يرغب طبيبك في مراقبتك بعناية إذا كنت تتناول هذه الأدویة ( بما في ذلك بعض أدوية فيروس نقص المناعة البشرية: ريتونافير، كوبيسيستات).</p><p dir="RTL">لا تنسى أن تُخبر الطبيب بأنّك تستخدم ديبروفوس في حال تم إخضاعك لفحوصات مخبريّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول ديبروفوس مع الأكل والشرب والكحول</strong></p><p dir="RTL">لا تشرب الكحول عند تناول ديبروفوس وذلك لأنّه قد يُسبّب لك مشاكل في المعدة أو الأمعاء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل، والرضاعة، والخصوبة</strong></p><p dir="RTL">تحدّثي إلى الطبيب قبل تناول هذا الدواء إذا كنت حامل أو مُرضع أو تنوين الحمل، وذلك لأنّه من غير المعروف إذا ما كان استخدام ديبروفوس آمنًا في حال الحمل أو الرضاعة.</p><p dir="RTL">في حال استخدام الكورتيكوستيرويد كعلاج في خلال الحمل، يجب مراقبة الأم والطفل جيدًا خلال الولادة وما بعدها.</p><p dir="RTL">يُرجى استشارة الطبيب أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة و استخدام الآلات</strong></p><p dir="RTL">بشكل عام، لن يؤثّر ديبروفوس على قدرتك على التفاعل أو التنسيق. لكن، في حال تناول جرعات كبيرة أو الخضوع للعلاج لمدة طويلة، قد يختبر بعض المرضى شعورًا مبالغًا به من النشوه، أو يُصابون بالنعاس، أو يعانون اضطرابات بصريّة، ممّا قد يؤثّر على قدرتهم على قيادة المركبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي ديبروفوس على 9 مجم بنزيل</strong><strong> </strong><strong>كحو</strong><strong>لي</strong><strong> في كل مل</strong><strong>.</strong></p><p dir="RTL">قد يسبب البنزيل الكحولي ردود فعل تحسسية. البنزيل الكحولي يرتبط بخطر الآثار الجانبية الشديدة بما في ذلك مشاكل التنفس (تسمى &quot;متلازمة اللهاث&quot;) عند الأطفال الصغار. لا تعطيه لمولودك الحديث الولادة (حتى عمر 4 أسابيع)، إلا إذا أوصى طبيبك بذلك. لا تستخدمي لأكثر من أسبوع في الأطفال الصغار (أقل من 3 سنوات)، ما لم ينصح بذلك طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسألي طبيبك أو الصيدلي للحصول على المشورة إذا كنت حاملاً أو مرضعة ، أو إذا كنت تعانين من مرض في الكبد أو الكلى. وذلك لأن كميات كبيرة من البنزيل الكحولي يمكن أن تتراكم في جسمك وقد تسبب آثارًا جانبية (تسمى &quot;الحماض الاستقلابي&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>ديبروفوس يحتوي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 مجم) لكل مل، وهذا يعني بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي ديبروفوس على ميثيل بارا هيدروكسي بانزوات </strong><strong>(E218)</strong><strong> وبروبيل بارا هيدروكسي بانزوات </strong><strong>(E216)</strong> &ndash;وهما مكوّنان قد يُسبّبان ردود فعل حساسيّة (ربّما متأخّرة) وفي حالات نادرة، مشاكل في التنفّس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم دائمًا ديبروفوس كما طلب منك الطبيب أو الصيدلي بالضبط. عليك مراجعة الطبيب أو الصيدلي في حال لم تكن متأكّدًا.</p><p dir="RTL">ديبروفوس محلول معلق للحقن، يجب رج العبوة قبل الاستخدام. يحقن هذه الحقنة عادةً الطبيب أو أخصائي رعاية صحيّة. يُحدّد الطبيب الجرعة حسب حاجاتك.</p><p dir="RTL">يُمكن إعطاء الحقنة عبر العضل، أو المفصل، أو في محيط المفصل، أو في الآفة، أو في الجلد، أو في الجراب. كما يُمكن حقنها في الأنسجة اللينة.</p><p dir="RTL">لا يُمكن اعطاء ديبروفوس عبر الوريد أو تحت الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول جرعة الزائدة &nbsp;من ديبروفوس</strong></p><p dir="RTL">سيتأكّد طبيبك بانتظام من أنّك تتناول &nbsp;الجرعة الصحيحة.</p><p dir="RTL">في حال تناولت جرعة زائدة من ديبروفوس، يُرجى الاتصال بالطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة</strong><strong> ديبروفوس</strong></p><p dir="RTL">لا تتناول جرعة مزدوجة للتعويض عن الجرعة التي نسيتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول</strong><strong> ديبروفوس</strong></p><p dir="RTL">لا تتوقّف فجأةً عن تناول ديبروفوس. على الطبيب أن يُخفّض لك الجرعة بالتدريج.</p><p dir="RTL">في حال كان لديك أي اسئلة أخرى حول استخدام هذا الدواء، يُرجى الاتصال بالطبيب أو بالصيدلي للحصول على المزيد من المعلومات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يُسبّب ديبروفوس، مثل كافةً الأدوية ، أعراض جانبيّةً، وإن كانت لا تُصيب الجميع.</p><p dir="RTL">تعتمد الأعراض الجانبيّة المرتبطة بالكورتيكوستيرويد، بما في ذلك ديبروفوس، على جرعة العلاج ومدّته.</p><p dir="RTL">قد تُصاب بالأعراض الجانبيّة التالية في خلال خضوعك للعلاج بواسطة ديبروفوس:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيّرات في دقات القلب وارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وهن وألم في العضلات وخسارة الكالسيوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس المياه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترقّق البشرة والتكدّم واحمرار الوجه والتأخّر في اندمال الجروح، وردود فعل حساسيّة، وزيادة التعرّق، والشرى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المشاكل في المعدة أو الأمعاء، مثل التقرّحات أو الشهق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنّجات أو الشعور المبالغ بالنشوه، والصعوبة في النوم (الأرق)، والدوار، والصداع، والتبدلات المزاجيّة، والاكتئاب الحاد، وفرط الهيوجيّة، وردود الفعل الذهانيّة، لا سيما لدى المرضى الذين لديهم تاريخ من المشاكل النفسيّة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العين، مثل الإصابة باعتام عدسة العين أوالماء الأزرق أو جحوظ العين من مكانها المعتاد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ الوجه، وحبّ الشباب، والاضطرابات في العادة الشهريّة والشهوة الجنسيّة، وارتفاع الحاجة إلى الانسولين وإلى الأدوية المضادة لداء السكري التي تُعطى عبر الفم لدى المرضى المصابين بداء السكري، وظهور أعراض داء السكري المتخفّي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأخّر نمو الجنين أو الطفل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إكتساب الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثبيط فحوصات البشرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حجب أعراض الإلتهاب ما وتفعيل التهاب كامن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض المقاومة للالتهابات، لا سيّما تلك العائدة إلى المتفطرات، وداء السل، والفطريّات المبيّضة، والفيروسات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض جانبيّة</strong></p><p dir="RTL">في حال التعرّض لأي أعراض جانبيّة، يُرجى التحدّث إلى الطبيب او الصيدلي. تشمل هذه الأعراض أي أعراض جانبيّة محتملة غير مدرجة في هذه النشرة. يمكنك الإبلاغ عن الأعراض جانبيّة عن طريق &quot;المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء&quot; المذكور في بند &quot;للإبلاغ عن الأعراض الجانبية&quot;. من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p dir="RTL">يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية</p><p dir="RTL">لا تستعمل الدواء إذا انتهت مدّة صلاحيته الواردة على العلبة بعد {EXP}. تاريخ انتهاء الصلاحية مكتوب على كل من اللاصق الداخلي والعبوة الخارجية.</p><p dir="RTL">يجب عدم التخلّص من الأدوية في النفايات المنزليّة أو مياه الصرف الصحي. اسأل الصيدلي عن كيفيّة التخلّص من الأدوية التي لم تعُد بحاجة إليها. ستُساهم هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادتان الفعّالتان هما بيتاميثازون &nbsp;ديبروبيونات 6.43 ملغم / مل (مايساوي 5 ملغ من بيتاميثازون) و بيتاميثازون ثنائي الصوديوم فوسفات 2.63 ملغ / مل (مايساوي 2 ملغ من بيتاميثازون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أما المكوّنات الأخرى فهي فوسفات هيدروجين ثنائي الصوديوم لا مائي* ، كلوريد الصوديوم ، ايديتات الصوديوم،&nbsp; بوليسوربات80، البنزيل الكحولي (E1519)، ميثيل بارا هيدروكسي بانزوات، بروبيل بارا هيدروكسي بانزوات &nbsp;، صوديوم كاربوكسي ميثل سيليلوز،&nbsp; ماكروغولز ، حمض الهيدروكلوريك، &nbsp;مياه للحقن، نيتروجين.</p><p dir="RTL">*شكل لا مائي لحقنة ديبروفوس ذات الاستعمال الواحد</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أمبولات ديبروفوس</p><p dir="RTL">عبوة من حقنة واحدة جاهزة للحقن من 1 مل</p><p dir="RTL">عبوة من 3 حقنات جاهزة للحقن من 1 مل</p><p dir="RTL">عبوة من حقنة واحدة جاهزة للحقن من 2 مل</p><p dir="RTL">عبوة من 3 حقنات جاهزة للحقن من 2 مل</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا يتمّ تسويق أحجام العلب كلّها.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحق</strong><strong>وق</strong><strong> التسويق</strong><strong>:</strong></p><p dir="RTL">إم إس دي بلجيكا بي في بي ايه/إس بي آر إل، كلوس دو لينكس، 5، 1200 بروكسل، بلجيكا</p><p dir="RTL"><strong>الشركة الصانعة:</strong></p><p dir="RTL">شيرينغ بلاو لابو إن في، إندستريبارك ٠ ٣، بي- ٢٢٢٠ هايست-أوب- دن بيرغ، بلجيكا</p><p dir="RTL">لا يُصرف الدواء إلا بوصفة طبيّة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة بتاريخ   أبريل 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Diprofos® Ampoule 5 mg + 2 mg/1 ml suspension for injection 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Betamethasone dipropionate 6.43 mg/ml (equivalent to 5 mg of betamethasone) and betamethasone disodium phosphate 2.63 mg/ml (equivalent to 2 mg of betamethasone).

Excipients with known effect: 
This medicinal product contains 9 mg of benzyl alcohol per mL.

Diprofos contains methyl parahydroxybenzoate (E218) and Diprofos contains propyl parahydroxybenzoate (E216)

For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Suspension for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Corticotherapy is an adjuvant treatment, not an alternative to conventional treatment.</p><p>&nbsp;</p><p>Intramuscular administration</p><p>Diprofos &nbsp;is indicated for the treatment of various rheumatic, dermatological and allergic diseases, as well as collagen and other disorders, known for their response to treatment with corticosteroids.</p><p>&nbsp;</p><p>Musculoskeletal administration (intraarticular and periarticular administration as well as direct administration into soft tissue)</p><p>As adjuvant treatment in short-term administration (to allow the patient to overcome an acute episode or exacerbation) for osteoarthritis, rheumatoid arthritis</p><p>&nbsp;</p><p>Intralesional administration</p><p>For dermatological disorders</p><p>&nbsp;</p><p>Local administration in the foot</p><p>As short-term adjuvant treatment (to allow the patient to overcome an acute episode or exacerbation) for bursitis under corns, calluses, heel spurs and hallux rigidus, and on a fifth toe; for synovial cysts, Morton&#39;s metatarsalgia, tenosynovitis and periostitis of the cuboid</p><p>&nbsp;</p><p><u>Typical situations</u></p><p>&nbsp;</p><p>Allergic conditions</p><p>Status asthmaticus, chronic bronchial asthma, seasonal and perennial allergic rhinitis, severe allergic bronchitis, contact dermatitis, atopic dermatitis, hay fever, angioneurotic edema, serum sickness, hypersensitivity reactions to medications or insect bites</p><p>&nbsp;</p><p>Rheumatic diseases</p><p>Osteoarthritis, rheumatoid arthritis, bursitis, lumbago, sciatica, coccydynia, acute gouty arthritis, torticollis, ganglion cyst, ankylosing spondylitis, radiculitis, exostosis, fasciitis</p><p>&nbsp;</p><p>Dermatological diseases</p><p>Atopic dermatitis (nummular eczema), neurodermatitis (circumscribed lichen simplex), contact dermatitis, severe solar actinitis, urticaria, hypertrophic lichen planus, necrobiosis lipoidica diabeticorum, alopecia areata, discoid lupus erythematosus, psoriasis, keloids, pemphigus, dermatitis herpetiformis, cystic acne</p><p>&nbsp;</p><p>Collagen diseases</p><p>During an exacerbation or as maintenance treatment in selected cases of systemic lupus erythematosus, polyarteritis nodosa, scleroderma and dermatomyositis</p><p>&nbsp;</p><p>Neoplastic diseases</p><p>Palliative treatment of leukemia and lymphoma in adults as well as acute leukemia in children</p><p>&nbsp;</p><p>Other conditions</p><p>Adrenogenital syndrome, ulcerative colitis, Crohn&#39;s disease, sprue, blood dyscrasias sensitive to corticosteroids, nephritis, nephrotic syndrome</p><p>&nbsp;</p><p>If a primary or secondary adrenocortical insufficiency is present, it can be treated by administering Diprofos , but mineralocorticoids should be added, if applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Shake before use.</p><p>&nbsp;</p><p>THE DOSE IS VARIABLE AND MUST BE ADJUSTED TO THE NEEDS OF THE INDIVIDUAL PATIENT, BASED ON THE CONDITION TREATED, ITS SEVERITY AND THE CLINICAL RESPONSE OF THE PATIENT.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The dose should be as low as possible and the period of administration as shortest as possible.</p><p>&nbsp;</p><p>The initial dose should be maintained or adjusted until a satisfactory response is obtained. If, after a reasonable time, no satisfactory clinical response is observed, treatment should be discontinued by a gradual reduction of the Diprofos &nbsp;dose, and another suitable treatment chosen.</p><p>&nbsp;</p><p>In case of positive response, determining the appropriate maintenance dose can be done by gradually decreasing the initial dose in small steps at suitable intervals, until the lowest dose that provides an adequate clinical response is reached.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Diprofos &nbsp;cannot be used for intravenous or subcutaneous administration.</p><p>&nbsp;</p><p><em>Systemic</em><em> </em><em>administration</em></p><p><em>&nbsp;</em></p><p>For systemic treatment, the treatment of the majority of conditions is initiated with the injection of 1 to &nbsp;2 ml, and repeated if necessary. The product is administered by deep intramuscular injection (IM) in the buttock. The dose and frequency of administration depends on the severity of the patient&#39;s condition and response to therapy. At first, it may be necessary to administer 2 ml during a critical illness such as systemic lupus erythematosus or status asthmaticus, which has been relieved by appropriate life-saving measures.</p><p>&nbsp;</p><p>Various dermatological diseases respond well to an IM injection of 1 ml of Diprofos , which can be repeated depending on how the disorder responds.</p><p>&nbsp;</p><p>In respiratory disorders, symptom relief has been obtained within a few hours after a Diprofos &nbsp;IM injection. Effective control of symptoms is obtained with 1 to 2 ml in the case of bronchial asthma, hay fever, allergic bronchitis and allergic rhinitis.</p><p>&nbsp;</p><p>For the treatment of acute or chronic bursitis, excellent results are obtained with an IM injection of 1 to 2 ml of Diprofos , repeated if necessary.</p><p>&nbsp;</p><p><em>Local</em><em> </em><em>administration</em></p><p><em>&nbsp;</em></p><p>The co-administration of a local anesthetic is rarely needed (the injection is virtually painless). If coadministration of a local anesthetic is desired, Diprofos &nbsp;can be mixed (in the syringe, not in the vial), with lidocaine hydrochloride (1% or 2%), with procaine hydrochloride (1% or 2%) or with a similar &nbsp;local anesthetic, using formulations that do not contain parabens. Avoid the use of anesthetics containing methylparaben, propylparaben, phenol, etc. The required dose of Diprofos &nbsp;is first withdrawn from the vial into the syringe. Next, the local anesthetic is aspirated and the syringe briefly shaken.</p><p>&nbsp;</p><p><strong>For</strong><strong> </strong><strong>acute</strong><strong> </strong><strong>bursitis:</strong><strong> </strong>(subdeltoid, subacromial and prepatellar)</p><p>an injection of 1 or 2 ml directly into the bursa relieves pain and restores the full range of motion within hours.</p><p>&nbsp;</p><p>For chronic bursitis:</p><p>When a favorable response has been obtained after acute treatment, the dose can be reduced.</p><p>&nbsp;</p><p>For tendinitis, tenosynovitis and peritendinitis:</p><p>acute: a single injection may already improve the patient&#39;s condition.</p><p>chronic: repetition may be necessary but this depends on the patient&#39;s condition.</p><p>&nbsp;</p><p>For rheumatoid arthritis and osteoarthritis:</p><p>After intrarticular administration of 0.5 to 2 ml of Diprofos , two to four hours may be sufficient to relieve the pain, soreness and stiffness associated with rheumatoid arthritis and osteoarthritis. In most cases, the duration of relief thus obtained, which varies widely for both diseases, is four weeks or more. Intraarticular injection of Diprofos &nbsp;is well tolerated by the joint and periarticular tissues.</p><p><u>Recommended dosages</u>:</p><p>large joints (e.g., knee, hip)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : 1 ml to 2 ml</p><p>average joints (e.g., elbow)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : 0.5 to 1 ml</p><p>small joints (e.g., hand)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; : 0.25 to 0.5 ml</p><p>&nbsp;</p><p>For dermatological disorders:</p><p>Dermatological conditions may respond to intralesional administration of Diprofos . The response of certain lesions not directly treated may be due to a slight systemic effect of the medicinal product.</p><p>0.2 ml/cm2&nbsp;of Diprofos &nbsp;is injected intradermally (not subcutaneously) using a tuberculin syringe fitted</p><p>with a 26 G needle. The total amount injected for all injection sites should not exceed 1 ml.</p><p>&nbsp;</p><p><strong>For foot disorders sensitive to corticosteroids</strong>. Bursitis under a corn can be overcome with two successive injections of 0.25 ml each. For conditions such as hallux rigidus (flexion deformity of the big toe), fifth toe varus (inward deflection of the fifth toe) and acute gouty arthritis, the onset of relief may occur rapidly. A tuberculin syringe fitted with a 25 G 1.9 cm needle is suitable for most injections in the foot.</p><p>Recommended doses at intervals of approximately one week: bursitis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; under a corn:&nbsp;&nbsp; 0.25 to 0.5 ml</p><p>under a calcaneal spur:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.5 ml</p><p>under a hallux rigidus:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.5 ml</p><p>on a fifth toe varus:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.5 ml</p><p>synovial cyst:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.25 to 0.5 ml</p><p>Morton&#39;s metatarsalgia:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.25 to 0.5 ml</p><p>tenosynovitis:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.5 ml</p><p>periostitis of the cuboid:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.5 ml</p><p>acute gouty arthritis:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.5 to 1 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1
-	Hypersensitivity to corticosteroids;
-	Systemic fungal infections.

In patients with idiopathic thrombocytopenic purpura, Diprofos  CANNOT be administered intramuscularly.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Diprofos &nbsp;cannot be used for intravenous or subcutaneous administration.</p><p>Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use.</p><p>&nbsp;</p><p>ANTISEPTIC TECHNIQUES ARE NECESSARY.</p><p><strong>&nbsp;</strong></p><p>Diprofos &nbsp;contains two betamethasone esters, one of which, betamethasone sodium phosphate, disappears rapidly from the injection site. Therefore, when using this product, the physician must take into account that this soluble portion of Diprofos &nbsp;may have a systemic effect.</p><p>&nbsp;</p><p>Eliminating or abruptly reducing administration during chronic use (at very high doses, after only a short time), or when an increase in corticosteroid requirements (following stress: infection, trauma, surgery) may precipitate adrenal insufficiency. It is therefore necessary to reduce the dose gradually. In stressful situations, it is sometimes necessary to administer corticosteroids again or to increase the dose.</p><p>&nbsp;</p><p>The dose reduction should be achieved under close medical supervision and it is sometimes necessary to monitor the patient for up to 1 year after cessation of prolonged or high-dose treatment.</p><p>&nbsp;</p><p>The symptoms of adrenal insufficiency are: discomfort, muscle weakness, mental disorders, lethargy, muscle and bone pain, desquamation of the skin, dyspnea, anorexia, nausea, vomiting, fever, hypoglycemia, hypotension, dehydration, and even death following abrupt discontinuation of the treatment. Treatment of adrenal insufficiency consists in administering corticosteroids, mineralocorticoids, water, sodium chloride and glucose.</p><p>&nbsp;</p><p>Rapid intravenous injection of high doses of corticosteroids can cause cardiovascular collapse; this is why the injection has to be administered over a 10-minute period.</p><p>&nbsp;</p><p>Rare instances of anaphylactoid/anaphylactic reactions with a possibility of shock have occurred in patients receiving parenteral corticosteroid therapy. Appropriate precautionary measures should be taken with patients who have a history of allergic reactions to corticosteroids.</p><p>&nbsp;</p><p>During prolonged corticosteroid therapy, consider switching from parenteral to oral administration after weighing the potential benefits and risks.</p><p>&nbsp;</p><p>For <u>intra-articular injections</u>, it is important to know that:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This type of administration can have local and systemic effects.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is essential to examine any liquid that may be present in the joint, in order to exclude a septic process.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid local injection into a previously infected joint.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A net increase in pain and local swelling, further decrease in joint mobility, fever and discomfort should raise the question of septic arthritis. If the diagnosis of infection is confirmed, appropriate antimicrobial treatment must be initiated.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not inject corticosteroids in unstable joints, infected areas or intervertebral spaces.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeated injections into osteoarthritis-affected joints can aggravate the destruction of the joint.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid injecting corticosteroids directly into tendons because tendon rupture may occur subsequently.</p><p>&nbsp;</p><p><u>Intramuscular injection of corticosteroids </u>should be performed deep in large muscle masses to avoid local tissue atrophy.</p><p>&nbsp;</p><p><u>The administration of a corticosteroid in soft tissue, or intralesional and intra-articular administration,</u> can induce systemic and local effects.</p><p>&nbsp;</p><p><em><u>Specific</u></em><em><u> groups</u></em><em><u> </u></em><em><u>at</u></em><em><u> risk</u></em></p><p>In diabetics, betamethasone may be used only for a short period and only under close medical supervision, given its glucocorticoid properties (transformation of glucose into proteins).</p><p>&nbsp;</p><p>There is an increase in the glucocorticoid effect in patients with hypothyroidism or cirrhosis.</p><p>&nbsp;</p><p>The use of Diprofos &nbsp;in ocular herpes simplex should be avoided, given the possibility of perforation of the cornea.</p><p>&nbsp;</p><p>Psychotic disorders can occur during treatment with corticosteroids. Predisposition to emotional instability or psychosis may worsen during treatment with corticosteroids.</p><p>&nbsp;</p><p>Caution is advised in case of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nonspecific ulcerative colitis, impending perforation, abscess and other pyogenic infections;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diverticulitis;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intestinal anastomosis;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastroduodenal ulcer;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal insufficiency;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypertension;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; osteoporosis;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; myasthenia gravis;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glaucoma;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute psychoses;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral and bacterial infections;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; growth retardation;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tuberculosis;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cushing&#39;s syndrome;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficult-to-treat epilepsy;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thromboembolism or thrombophlebitis tendencies;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pregnancy.</p><p>&nbsp;</p><p>Since the complications of corticosteroid treatment depend on the dose and duration of treatment, the risk/benefit ratio for each patient regarding the dose and duration of treatment needs to be considered.</p><p>&nbsp;</p><p>Corticosteroids may mask certain signs of infection or make the detection of infection more difficult. Due to a decrease in resistance, new infections can occur during use.</p><p>&nbsp;</p><p>Prolonged use can lead to a posterior subcapsular cataract (especially in children) or to glaucoma, which can damage the optic nerves and may exacerbate secondary ocular infections due to fungi or viruses.</p><p>In case of prolonged treatment (over 6 weeks), it is necessary to undergo regular ophthalmological examinations.</p><p>Average and large doses of corticosteroids can induce hypertension, fluid retention and increased potassium excretion. These effects are less likely to occur with the synthetic derivatives, except when used at high doses. A low sodium diet and potassium supplements may be considered. All corticosteroids increase calcium excretion.</p><p>&nbsp;</p><p>PATIENTS ON CORTICOTHERAPY CANNOT RECEIVE THE FOLLOWING TREATMENTS:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SMALLPOX VACCINATION;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER METHODS OF IMMUNIZATION (ESPECIALLY AT HIGH DOSE) BECAUSE OF THE RISK OF NEUROLOGICAL COMPLICATIONS AND INADEQUATE ANTIBODY RESPONSE.</p><p>&nbsp;</p><p>However, patients receiving corticosteroids as replacement therapy may be immunized (e.g., Addison&#39;s disease).</p><p>Patients, especially children, receiving immunosuppressive doses of corticosteroids should be warned to avoid exposure to chickenpox or measles.</p><p>&nbsp;</p><p>In case of active tuberculosis, corticosteroids should be limited to cases of fulminating or disseminated tuberculosis, in which corticosteroids are used in combination with a suitable anti-tubercular treatment regimen.</p><p>&nbsp;</p><p>If corticosteroids are indicated in patients with latent tuberculosis or reacting to tuberculin, strict monitoring is necessary because disease reactivation can occur. During prolonged corticosteroid therapy, patients should receive chemoprophylaxis.</p><p>&nbsp;</p><p>If using rifampicin in a chemoprophylaxis program, its enhancing effect on the metabolic hepatic clearance of corticosteroids must be remembered; it may be necessary to adjust the dose of the corticosteroid.</p><p>&nbsp;</p><p>As corticosteroids can disturb the growth of infants and children and inhibit the endogenous production of corticosteroids, it is important to monitor their growth and development carefully in the event of prolonged treatment.</p><p>&nbsp;</p><p>Corticosteroids may sometimes alter the motility and number of spermatozoa in some patients.</p><p>&nbsp;</p><p><strong>Diprofos contains benzyl alcohol</strong></p><p>Benzyl alcohol may cause allergic reactions.</p><p>Benzyl alcohol has been linked with the risk of severe side effects including breathing problems</p><p>(called &ldquo;gasping syndrome&rdquo;) in young children. The minimum amount of benzyl alcohol at which</p><p>toxicity may occur is not known. Do not administer to premature babies or newborns at term (up to 4 weeks). Do not administer for more than a week in young children (less than 3 years old).</p><p>Large amounts of benzyl alcohol may cause metabolic acidosis. Special precautions should be taken when prescribing Diprofos to neonates, pregnant or breast-feeding patients and patients with liver or kidney disease.</p><p>&nbsp;</p><p><strong>Diprofos contains sodium</strong></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per injection, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p><strong>Diprofos &nbsp;contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216)</strong></p><p>which may cause allergic reactions (possibly delayed) and exceptionally, bronchospasm. Visual disturbance</p><p>Visual disturbance may be reported with systemic and topical (including, intranasal, inhaled and intraocular) corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes of visual disturbances which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interaction with other medicinal products:</u></p><p>&nbsp;</p><p>Combination with phenobarbital, rifampin, phenytoin or ephedrine may enhance the metabolism of corticosteroids, resulting in a decrease in therapeutic effect.</p><p>&nbsp;</p><p>PATIENTS ON CORTICOTHERAPY CANNOT RECEIVE THE FOLLOWING TYPES OF TREATMENT:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SMALLPOX VACCINATION;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER METHODS OF IMMUNIZATION (ESPECIALLY AT HIGH DOSE) BECAUSE OF THE RISK OF NEUROLOGICAL COMPLICATIONS AND INADEQUATE ANTIBODY RESPONSE.</p><p>&nbsp;</p><p>However, patients receiving corticosteroids as replacement therapy may be immunized (e.g., Addison&#39;s disease).</p><p>&nbsp;</p><p>The combination with diuretics such as thiazides may increase the risk of glucose intolerance.</p><p>&nbsp;</p><p>Patients simultaneously receiving a corticosteroid and an estrogen must be monitored for excessive corticosteroid effects.</p><p>&nbsp;</p><p>The simultaneous administration of corticosteroids and cardiac glycosides may increase the risk of arrhythmias or digitalis toxicity related to hypokalemia. Often, patients using cardiac glycosides also take diuretics which induce potassium depletion; in this case, it is essential to conduct potassium level determinations. Corticosteroids may worsen the potassium depletion caused by amphotericin B. In all patients taking one of these medication combinations, serum electrolytes, particularly serum potassium, should be closely monitored.</p><p>&nbsp;</p><p>The simultaneous use of corticosteroids and coumarin-type anticoagulants may increase or decrease the anticoagulant effects, which may require a dosage adjustment. In patients taking anticoagulants in combination with glucocorticoids, the possibility of gastrointestinal ulceration induced by corticosteroids, or increased risk of internal bleeding, must be considered.</p><p>&nbsp;</p><p>Corticosteroids may decrease the concentration of salicylates in the blood. When lowering the dose of corticosteroids or discontinuing treatment, patients should be checked for the presence of salicylism. The combination of glucocorticoids with salicylates may increase the frequency and severity of a gastrointestinal ulcer.</p><p>&nbsp;</p><p>The combination with non-steroidal anti-inflammatories or alcohol can lead to an increased risk of developing a gastrointestinal ulcer or the worsening of an existing ulcer.</p><p>&nbsp;</p><p>In diabetics, it is sometimes necessary to adjust the dose of oral antidiabetic agents or insulin, given the intrinsic hyperglycemic effect of glucocorticoids.</p><p>&nbsp;</p><p>Combination with somatropin may inhibit the response to this hormone. Betamethasone doses greater than 300-450 &micro;g (0.3 to 0.45 mg) per m2&nbsp;of body surface area per day should be avoided during administration of somatotropin.</p><p>&nbsp;</p><p>Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Other forms of interactions</u>:</p><p><em><u>Laboratory </u></em><em><u>tests</u></em></p><p><em>&nbsp;</em></p><p>Corticosteroids may influence the nitro blue tetrazolium reduction test and produce false negative results.</p><p>&nbsp;</p><p>When the patient is treated with corticosteroids, this fact should be taken into account when interpreting the parameters and laboratory tests (skin tests, thyroid hormone levels, etc.).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given the lack of adequate teratogenic studies in humans, glucocorticoids can only be administered during pregnancy, breast-feeding and in women of fertile age after having thoroughly evaluated the health benefits and potential risks of these medications for the mother, the embryo or the fetus.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>When prenatal corticotherapy is indicated, the advantages and disadvantages need to be weighed and the clinical benefit compared to the side effects (including the inhibition of growth and the increased risk of infection).</p><p>&nbsp;</p><p>In some cases it is necessary to continue the corticosteroid treatment during pregnancy or even increase the dose (e.g., in replacement corticotherapy).</p><p>&nbsp;</p><p>Intramuscular administration of betamethasone induces a significant decrease in the frequency of dyspnea in the fetus when the product is administered more than 24 hours before delivery (before the 32nd&nbsp;week of gestation).</p><p>&nbsp;</p><p>Published data show that the prophylactic use of corticosteroids after the 32nd&nbsp;week of pregnancy is still controversial. Therefore, the physician should weigh the benefits and potential risks for the mother and fetus when using corticosteroids after the 32nd&nbsp;week of pregnancy.</p><p>&nbsp;</p><p>Corticosteroids are not indicated to treat hyaline membrane disease after birth.</p><p>&nbsp;</p><p>In prophylactic treatment of hyaline membrane disease in premature infants, do not administer corticosteroids to pregnant women with preeclampsia or eclampsia or with signs of placental lesions.</p><p>&nbsp;</p><p>Children born to mothers given high doses of corticosteroids during pregnancy should be carefully monitored to detect any signs of adrenal insufficiency.</p><p>&nbsp;</p><p>When betamethasone injections have been administered to mothers before birth, infants show a transient inhibition of fetal growth hormone and presumably of the pituitary hormones that regulate the production</p><p>&nbsp;</p><p>of steroids, both in the definitive zones and fetal zones of the fetal adrenals. However, inhibition of fetal hydrocortisone has not interfered with the pituitary-adrenal responses to stress after birth.</p><p>&nbsp;</p><p>&nbsp;</p><p>As corticosteroids readily cross the placenta, newborns and infants born to mothers who received corticosteroids during most or part of their pregnancy should be subject to careful examination in order to detect a possible, though very rare, congenital cataract.</p><p>&nbsp;</p><p>Women who received corticosteroids during pregnancy should be monitored during and after contractions and during childbirth to detect adrenal insufficiency due to the stress caused by birth.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>&nbsp;</p><p>Corticosteroids cross the placental barrier and are excreted in breast milk.</p><p>&nbsp;</p><p>Given that Diprofos &nbsp;may induce adverse reactions in breast-fed infants, a decision must be made whether to stop breast-feeding or stop the medicinal product, taking into account the importance of the medicinal product for the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Caution should be exercised concerning the central effects when administered at high doses (euphoria, insomnia) and with regard to the vision disorders that can occur with prolonged treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions observed with Diprofos , which are the same as those mentioned for other corticosteroids, are related to both dose and duration of treatment.</p><p>&nbsp;</p><p>Among the adverse reactions to corticosteroids in general, the following effects are to be particularly noted:</p><p>Fluid and electrolyte disorders:</p><p>Sodium retention - Potassium loss - Hypokalemic alkalosis - Fluid retention - Congestive heart failure in susceptible patients - Hypertension;</p><p>&nbsp;</p><p>Musculoskeletal disorders:</p><p>Muscular weakness - Loss of muscle mass - Aggravation of myasthenic symptoms in myasthenia gravis - Osteoporosis with sometimes severe bone pain and spontaneous fractures (vertebral compression fractures) - Aseptic bone necrosis (femoral and humeral head) - Tendon rupture - Steroid myopathy - Pathological fractures - Joint instability;</p><p>&nbsp;</p><p>Skin disorders:</p><p>Skin atrophy - Delayed healing - Thin and fragile skin - Petechiae - Bruising - Allergic dermatitis - Angioneurotic edema - Facial erythema - Increased sweating - Urticaria;</p><p>&nbsp;</p><p>Digestive disorders:</p><p>Gastric ulcer with bleeding and possible perforation - Pancreatitis - Abdominal distension - Intestinal perforation - Ulcerative esophagitis - Nausea - Vomiting;</p><p>&nbsp;</p><p>Neurological disorders:</p><p>Seizures - Vertigo - Headache - Migraines - Increased intracranial pressure (pseudotumor cerebri);</p><p>&nbsp;</p><p>Psychiatric disorders:</p><p>Euphoria - Mood Disorders - Personality changes and severe depression - Hyperirritability - Insomnia - Psychotic reactions especially in patients with a psychiatric history - Depression;</p><p>&nbsp;</p><p>Ophthalmic disorders:</p><p>Increased intraocular pressure (pseudotumor cerebri: see neurological); Glaucoma - Posterior subcapsular cataract &ndash; Exophthalmos- Vision blurred (see also section 4.4).</p><p>&nbsp;</p><p>Endocrine disorders :</p><p>Clinical symptoms of Cushing&#39;s syndrome - Menstrual disorders - Increased need for insulin or oral antidiabetic agents in diabetics - Inhibition of fetal child growth - Reduced tolerance to carbohydrates - Signs of latent diabetes mellitus - Secondary inhibition of the pituitary and the adrenal cortex, especially harmful in case of stress (such as trauma, surgery and disease);</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:163.1pt;margin-top:11.45pt;width:3.6pt;
 height:.5pt;z-index:-251658240;mso-position-horizontal-relative:page'
 coordorigin="3262,229" coordsize="72,10">
 <v:shape id="_x0000_s1027" style='position:absolute;left:3262;top:229;width:72;
  height:10' coordorigin="3262,229" coordsize="72,10" path="m3262,234r72,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="6" height="1" src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Metabolic disorders<em>:</em></p><p>Negative nitrogen balance with protein degradation - Lipomatosis - Weight gain;</p><p>&nbsp;</p><p>Immunity disorders :</p><p>Corticosteroids can cause an inhibition of skin tests, mask the symptoms of infection and active a latent infection. They can also decrease resistance to infection, especially when due to mycobacteria, tuberculosis, Candida albicans or viruses.</p><p>&nbsp;</p><p>Other:</p><p>Anaphylactic or allergic reactions, hypotensive reactions or reactions related to shock.</p><p>&nbsp;</p><p>THE FOLLOWING ADVERSE REACTIONS MAY BE OBSERVED DURING PARENTERAL CORTICOTHERAPY:</p><p>Rare cases of blindness associated with intralesional treatment of the face and head - Hyperpigmentation or hypopigmentation - Subcutaneous and cutaneous atrophy - Sterile abscess - Post-injection exacerbation (after intra-articular use) - Charcot arthropathy.</p><p>&nbsp;</p><p>After repeated intra-articular administration, joint damage may occur. There is a risk of contamination.</p><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u>:</p><p>Acute overdosage of glucocorticoids, including betamethasone, is not life-threatening.</p><p>&nbsp;</p><p>Except in extreme doses, it is unlikely that a few days of glucocorticoid overdose will have negative consequences in the absence of specific contraindications such as diabetes, glaucoma, active peptic ulcer, or when administering medications such as digitalis, coumarin anticoagulants or potassium-sparing diuretics.</p><p>&nbsp;</p><p><u>Measures</u>:</p><p>The complications resulting from the metabolic effects of corticosteroids, or the deleterious effects of the main disease or concomitant diseases, as well as the complications resulting from medication interactions, must be treated appropriately. It is necessary to ensure adequate fluid intake and monitor electrolytes in the serum and urine, paying particular attention to the sodium and potassium balance. If necessary, any electrolyte imbalance must be treated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Corticosteroids for systemic use, glucocorticoids, ATC code: H02A B01. Betamethasone is a synthetic glucocorticoid (9 alpha-fluoro-16 beta-methylprednisolone).</p><p>Betamethasone has strong anti-inflammatory, immunosuppressive and anti-allergic activity.</p><p>&nbsp;</p><p>Betamethasone has no clinically significant mineralocorticoid effect. Glucocorticoids diffuse across cell membranes and form complexes with specific cytoplasmic receptors. These complexes then enter the</p><p>cell nucleus, bind to DNA (chromatin) and stimulate the transcription of messenger RNA and the protein synthesis of various enzymes. These are finally responsible for the effects observed in systemic glucocorticoid use. In addition to their significant effect on the inflammatory and immune processes, glucocorticoids also influence the metabolism of carbohydrates, proteins and lipids. Finally, they also have an effect on the cardiovascular system, skeletal muscles and the central nervous system.</p><p>&nbsp;</p><p>Effect on inflammatory and immune processes:</p><p>The anti-inflammatory, immunosuppressive and anti-allergic properties of glucocorticoids are responsible for a very substantial part of their therapeutic applications. The main aspects of these properties are: reduction in the number of immuno-active cells at the inflammatory site, reduced vasodilation, stabilization of lysosomal membranes, inhibition of phagocytosis, reduced production of prostaglandins and related substances.</p><p>The anti-inflammatory activity is about 25 times greater than that of hydrocortisone, and 8 to 10 times greater than that of prednisolone (on a weight basis).</p><p>&nbsp;</p><p>Effect on the metabolism of carbohydrates and proteins:</p><p>Glucocorticoids stimulate protein catabolism. In the liver, the released amino acids are converted into glucose and glycogen by the process of gluconeogenesis. Glucose uptake in peripheral tissues decreases, which leads to hyperglycemia and glucosuria, especially in patients with a diabetic predisposition.</p><p>&nbsp;</p><p>Effect on lipid metabolism:</p><p>Glucocorticoids have lipolytic activity. This lipolysis is more pronounced in the limbs. Glucocorticoids also have a lipogenic effect that occurs mainly in the trunk, neck and head. As a whole, these effects lead to a redistribution of fat deposits.</p><p>&nbsp;</p><p>The maximum pharmacological activity of corticosteroids appears later than the peak serum levels, suggesting that most effects of these medications are not based on direct activity of the medicinal product, but on the modification of enzyme activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Betamethasone disodium phosphate and betamethasone dipropionate are resorbed from the injection site and induce therapeutic effects and other pharmacological effects, both locally and systemically.</p><p>&nbsp;</p><p>Betamethasone disodium phosphate is highly soluble in water and is metabolized in the body into betamethasone, the biologically active steroid. 2.63 mg of betamethasone disodium phosphate is equivalent to 2 mg of betamethasone.</p><p>&nbsp;</p><p>Prolonged activity is obtained using betamethasone dipropionate. This practically insoluble product constitutes a deposit, so that it is less rapidly resorbed and relieves symptoms longer.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Blood</em></strong><strong><em> </em></strong><strong><em>levels</em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>Intramuscular</em></strong><strong><em> </em></strong><strong><em>injection</em></strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong><em>betamethasone</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>natrii</em></strong><strong><em> </em></strong><strong><em>phosphas</em></strong></p></td><td style="vertical-align:top"><p><strong><em>dipropionas</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maximum plasma concentration</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plasma half-life after a single dose</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excretion</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Biological half-life</p></td><td style="vertical-align:top"><p>1 hour after administration</p><p>&nbsp;</p><p>&nbsp;</p><p>from 3 to 5 hours</p><p>&nbsp;</p><p>&nbsp;</p><p>24 hours</p><p>&nbsp;</p><p>36 to 54 hours</p></td><td style="vertical-align:top"><p>Slow absorption</p><p>&nbsp;</p><p>&nbsp;</p><p>Progressive metabolism</p><p>&nbsp;</p><p>&nbsp;</p><p>More than 10 days</p></td></tr></tbody></table><p>&nbsp;</p><p>Betamethasone is metabolized in the liver. Betamethasone binds primarily to albumin. In patients with a liver disorder, its clearance is slower or delayed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium phosphate dihydrate (disodium phosphate anhydrous for Diprofos &nbsp;Disposable Syringe), sodium chloride, disodium edetate, polysorbate 80, benzyl alcohol (E1519), methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium carboxymethylcellulose, macrogols, hydrochloric acid, water for injections, nitrogen</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The concomitant use of a local anesthetic is rarely necessary. If coadministration of a local anesthetic is desired, Diprofos &nbsp;can be mixed (in the syringe, not in the vial), with lidocaine hydrochloride</p><p>(1% or 2%), with procaine hydrochloride (1% or 2%) or with a similar local anesthetic, using formulations that do not contain parabens. Avoid the use of anesthetics containing methylparaben, propylparaben, phenol, etc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
18 months

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Diprofos &nbsp;Ampoule:</p><p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Diprofos &nbsp;Ampoule:</u></p><p>Boxes of 1 ampoule of 1 ml Boxes of 3 ampoules of 1 ml Boxes of 1 ampoule of 2 ml Boxes of 3 ampoules of 2 ml</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder: 
MSD Belgium BVBA/SPRL, Close du Lynx,5, 1200 Brussels, Belgium

Manufacturer: 
Schering-Plough Labo N.V, Industriepark 30, B-22220 Heist-op-den-Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
04/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>